Genic alterations in oral and head and neck squamous cell carcinomas: Analysis of international literature;Anomalies géniques dans les carcinomes épidermoïdes des voies aérodigestives supérieures: Analyse de la littérature internationale

Pathologie Biologie

Volumn 51, Issue 3, 2003, Pages 176-184

  Raybaud, H ^a   Odin, G ^b   Fafet, A ^a   Santini, J ^b   Monteil, R A ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b PASTEUR HOSPITAL   (France)

Author keywords

Cell cycle protein; Head and neck; Oncogene; Oral squamous cell carcinoma; Squamous cell carcinoma; Telomerase; Tumour suppressor gene

Indexed keywords

ANTINEOPLASTIC AGENT; ARF PROTEIN; CARCINOGEN; CYCLIN D1; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; TELOMERASE;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME REACTIVATION; GENE AMPLIFICATION; GENE DELETION; GENE INACTIVATION; GENE INTERACTION; GENE MUTATION; HEAD CANCER; HUMAN; MITOSIS RATE; MOUTH CARCINOMA; NECK CANCER; ONCOGENE; ONCOGENE MYC; ONCOGENE RAS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0038377116     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0369-8114(03)00016-6     Document Type: Review

References (81)

1. Viallard JF, Lacombe F, Belloc F, Pellegrin JL, Reiffers J. Mécanismes moléculaires contrôlant le cycle cellulaire: aspects fondamentaux et implications en cancérologie. Cancer radiothérapie 2001;5:109-29.
2. Akervall JA, Michalides RJ, Mineta H, Balm A, Borg A, Dictor MR, et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 1997;79:380-9.
3. Michalides RJ, van Veelen NM, Kristel PM, Hart AA, Loftus BM, Hilgers FJ, et al. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head and Neck Surg 1997;123:497-502.
4. Xu J, Gimenez-Conti IB, Cunningham JE, Collet AM, Luna MA, Lanfranchi HE, et al. Alterations of p53, cyclin D1, Rb and H-ras in human oral carcinomas related to tobacco use. Cancer 1998;83:204-12.
5. Bova RJ, Quinn DI, Nankervis JS, Cole IE, Sheridan BF, Jensen MJ, et al. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 1999;5:2810-9.
6. Kuo MY, Lin CY, Hahn LJ, Cheng SJ, Chiang CP. Expression of cyclin D1 is correlated with poor prognosis in patients with areca quid chewing-related oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 1999;28:165-9.
7. Shintani S, Mihara M, Ueyama Y, Matsumura T, Wong DT. Cyclin D1 overexpression associates with radiosentivity in oral squamous cell carcinoma. Int J cancer 2001;96:159-65.
8. Hsieh JK, Chan FSG, O'Connor DJ, Mittnacht S, Zhong S, Lu X. Rb regulates the stability and the apoptotic function of p53 via mdm2. Mol Cell 1999;3:181-93.
9. Gleich LL, Li YQ, Biddinger PW, Gartside PS, Stambrook PJ, Pavelic ZP, et al. The loss of heterozygosity in retinoblastoma and p53 suppressor genes as a prognostic indicator for head and neck cancer. Laryngoscope 1996;106:1378-81. Laryngoscope 1996;106:1378-81. Laryngoscope erratum 1997;107:148.
10. Gleich LL, Li YQ, Biddinger PW, Gartside PS, Stambrook PJ, Pavelic ZP, et al. The loss of heterozygosity in retinoblastoma and p53 suppressor genes as a prognostic indicator for head and neck cancer. Laryngoscope 1996;106:1378-81. Laryngoscope 1996;106:1378-81. Laryngoscope erratum 1997;107:148.
11. Pavelic ZP, Lasmar M, Pavelic L, Sorensen C, Stambrook PJ, Zimmermann N, et al. Absence of retinoblastoma gene product in human primary oral cavity carcinomas. Eur J Cancer B Oral Oncol 1996;32B:347-51.
12. Pande P, Mathur M, Shukla NK, Ralhan R. pRb and p16 protein alterations in human oral tumorigenesis. Oral Oncol 1998;34:396-403.
13. El-Naggar AK, Lai S, Clayman GL, Zhou JH, Tucker SA, Myers J, et al. Expression of p16, Rb and cyclin D1 gene products in oral and laryngeal squamous carcinoma: biological and clinical implications. Hum Pathol 1999;30:1013-8.
14. Lane DP. Cancer, P53, guardian of the genome. Nature 1992;358:15-6.
15. Soussi T. Cycle cellulaire et apoptose: le géne suppresseur de tumeur p53. médecine/sciences 2000;16:467-9.
16. Vousden KH. P53: death strar. Cell 2000;103:691-4.
17. Nakano K, Vousden KH. Puma, a novel proapoptotic gene, is induced by p53. Mol Cell 2001;7:683-94.
18. Raybaud-Diogene H, Tetu B, Morency R, Fortin A, Monteil RA. p53 overexpression in head and neck squamous cell carcinoma: review of the literature. Eur J Cancer B Oral Oncol 1996;32B:143-9.
19. Tatemoto Y, Osaki T, Yoneda K, Yamamoto T, Ueta E, Kimura T. Expression of p53 and p21 proteins in oral squamous celle carcinoma: correlation with lymp node metastasis and response to chemoradiotherapy. Pathol Res Pract 1998;194:821-30.
20. Chiang CP, Huang JS, Wang JT, Liu BY, Kuo YS, Hahn LJ, et al. Expression of p53 protein correlates with decreased survival in patients with areca quid chewing and smoking-associated oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 1999;28:76-7.
21. Osaki T, Kimura T, Tatemoto Y, Dapeng L, Yoneda K, Yamamoto T. Diffuse mode of tumor cell invasion and expression of mutant p53 protein but not of p21 protein are correlated with treatment failure in oral carcinomas and their metastatic foci. Oncology 2000;59:36-43.
22. Raybaud-Diogene H, Fortin A, Morency R, Roy J, Monteil RA, Tetu B. Markers of radioresistance in squamous cell carcinomas of head and neck: a clinicopathologic and immunohstochemical study. J Clin Oncol 1997;15:1030-8.
23. Raybaud H, Fortin A, Bairati I, Morency R, Monteil RA, Tetu B. Nuclear DNA content, an adjunct to p53 and Ki-67 as a marker of resistance to radiation therapy in oral cavity and pharyngeal squamous cell carcinoma. Int J Oral Maxillofac Surg 2000 Feb;29(1):36-41.
24. Couture C, Raybaud-Diogéne H, Têtu B, Bairati I, Murry D, Allard J, Fortin A. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer 2002;94:713-22.
25. Hiranuma H, Jikko A, Maeda T, Matumura S, Murakami S, Fukuda Y, et al. An analysis of the prognostic significance of p53 status for squamous cell carcinomas of oral cavity treated by radiotherapy. Oral Oncol 1998;34:513-8.
26. Stoll C, Baretton G, Ahrens C, Lohrs U. Prognostic significance of apoptosis and associated factors in oral squamous cell carcinoma. Virchows Arch 2000;436:102-8.
27. Lazarus P, Sheikh SN, Ren Q, Schantz SP, Stern JC, Richie Jr JP, et al. p53, but not p 16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1 and GSTM1 polymorphic genotypes and patient tobacco use. Carcinogenesis 1998;19:509-14.
28. Thomas S, Brennan J, Martel G, Frazer I, Montesano R, Sidransky D, et al. Mutations in the conserved regions of p53 are infrequent in betel-associated oral cancers from Papa-New Guinea. Cancer Res 1994;54:3588-93.
29. Honda R, Yasuda H. Association of p19(ARF) with mdm2 inhibits ubiquitin ligase activity of mdm2 for tumor suppressor p53. EMBO J 1999;18:22-7.
30. Millon R, Muller D, Schultz I, Salvi R, Ghnassia JP, Frebourg T, et al. Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance. Oral Oncol 2001 Dec;37(8):620-31.
31. Matsumura T, Yoshihama Y, Kimura T, Shintani S, Alcalde RE. p53 and MDM2 expression in oral squamous cell carcinoma. Oncology 1996;53:308-12.
32. Agarwald S, Mathur M, Srivastava A, Ralhan R. MDM2/p53 co-expression in oral premalignant and malignant lesions: potentiel diagnostic implications. Oral Oncol 1999;35:209-16.
33. Regezi JA, Dekker NP, McMillan A, Ramirez-Amador V, MenesesGarcia A, Ruiz-Godoy Rivera LM, et al. p53, p21, Rb and MDM2 proteins in tongue carcinoma from patients 〈35 versus〉75 years. Oral Oncol 1999;35:379-83.
34. Li XJ, Murai M, Koyama T, Wang DY, Hashimoto K. MDM2 overexpression with alteration of the p53 protein and gene status in oral carcinogenesis. Jpn J Cancer Res 2000;91:492-8.
35. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al, WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
36. Agarwald S, Mathur M, Shukla NK, Ralhan R. Expression of cyclin dependent kinase inhibitor p21waf1/cip1 in premalignant and malignant oral lesions: relationship with p53 status. Oral Oncol 1998;34:353-60.
37. Yoneda K, Yamamoto T, Osaki T. p53- and p21-independent apoptosis of squamous cell carcinoma cells induced by 5-fluorouracil and radiation. Oral Oncol 1998 Nov;34(6):529-37.
38. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366(6456):704-7.
39. INKa/MTSI/CDKN2 locus to human malignancies. Progress in cell cycle Res, 3. 1997. p. 109-24.
40. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998 Mar 20;92(6):713-23.
41. Matsuda H, Konishi N, Hiasa Y, Hayashi I, Tsuzuki T, Tao M, et al. Alterations of p16/CDKN2, p53 and RAS genes in oral squamous cell carcinomas and premalignant lesions. J Oral Pathol Med 1996;25:232-8.
42. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, et al. High frequency of p16(CDKN2/MTS/1NK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630-3.
43. Jares P, Fernandez PL, Nadal A, Cazorla M, Hernandez L, Pinyol M, et al. p16MTS1/CDK41 mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx. Oncogene 1997;15:1453-67.
44. Warnakulasuriya K, Tavassoli M, Johnson NW. Relationship of p53 overexpression to other cell cycle regulatory proteins in oral squamous cell carcinoma. J Oral Pathol Med 1998;27:376-81.
45. Wu CL, Roz L, McKown S, Sloan P, Read AP, Holland S, et al. DNA studies underestimate the major role of CDKN2A inactivation in oral and oropharyngeal squamous cell carcinomas. Genes Chromosomes Cancer 1999;25:16-25.
46. Ito T, Fujieda S, Tsuzuki H, Sunaga H, Fan G, Sugimoto C, et al. Decreased expression of Bax is correlated with poor prognosis in oral and oropharyngeal carcinoma. Cancer Lett 1999;140:81-91.
47. Jordan RC, Bradley G, Slingerland J. Reduced levels of the cell-cycle inhibitor p27kip1 in epithelial dysplasia and carcinoma of the oral cavity. Am J Pathol 1998;152:585-90.
48. Fujieda S, Inuzuka M, Tanaka N, Sunaga H, Fan GK, Ito T, et al. Expression of p27 is associated with bax expression and spontaneous apoptosis in oral and oropharyngeal carcinoma. Int J Cancer 1999;84:315-32.
49. Schoelch ML, Regezi JA, Dekker NP, Ng IO, McMillan A, Ziober BL, et al. Cell cycle proteins and the development of oral squamous cell carcinoma. Oral Oncol 1999;35:333-42.
50. Venkatesan TK, Kuropkat C, Caldarelli DD, Panje WR, Hutchinson JC, Chen S, et al. Prognostic significance of p27 expression in carcinoma of the oral cavity and oropharynx. Laryngoscope 1999;109:1329-33.
51. Tsujimoto Y, Cossman J, Involvement of the bcl2 gene in human follecular lymphoma. Science 1985;228:1440-3.
52. Antonsson B, Martinou JC. The bcl2. Experimental Cell Research 2000;256:50-7.
53. Gallo O, Boddi V, Calzolari A, Simonetti L, Trovati M, Bianchi S. A,bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy. Clin Cancer Res 1996;2:261-7.
54. Jordan RC, Catzavelos GC, Barrett AW, Speight PM. Differential expression of bcl-2 and bax in squamous cell carcinomas of the oral cavity. Eur J Cancer B Oral Oncol 1996;32:394-400.
55. Kitada S, Krajewski S, Miyashita T, Krajewska M, Reed JC, Gammaradiation induces upregulation of bax protein and apoptosis in radiosensitive cells in vivo. Oncogene 1996;12:187-92.
56. Wilson GD, Grover R, Richman PI, Daley FM, Saunders MI, Dische S. Bcl-2 expression correlates with favourable outcome in head and neck cancer treated by accelerated radiotherapy. Anticancer Res 1996;16:2403-8.
57. Friedman M, Grey P, Venkatesan TK, Bloch I, Chawla P, Caldarelli DD, et al. Pronostic significance of bcl-2 expression in localized squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol 1997;106:445-50.
58. Singh BB, Chandler Jr FW, Whìtaker SB, Forbes-Nelson AE. Immunohistochemical evaluation of bcl-2 oncoprotéine in oral dysplasia and carcinoma. Oral Med Oral Pathol Oral Radiol Endod 1998;85:692-8.
59. Sakamuro D, Prendergast GC. New Myc-interacting proteins: a 2nd Myc network emerges. Oncogene 1999;18:2942-54.
60. Field JK, Spandidos DA, Stell PM, Vaughan ED, Evan GI, Moore JP. Elevated expression of the c-myc oneoprotein correlates with poor pronosis in head and neck squamous cell carcinoma. Oncogene 1989;4:1463-8.
61. Haughey BH, von Hoff DD, Windle BE, Wahl GM. Mock P.M., c-myc oncogene copy number in squamous cell carcinoma of the head and neck. Am J Otolaryngol 1992;13:168-71.
62. Saranath D, Bhoite LT, Deo MG. Molecular lesions in human oral cancer: the Indian scene. Eur J Cancer B Oral Oncol 1993 Apr;29B(2):107-12.
63. Sugerman PB, Joseph BK, Savage NW. Review article: The role of oncogenes, tumour suppressor genes and growth factors in oral squamous cell carcinoma: a case of apoptosis versus proliferation. Oral Dis 1995;1:172-88.
64. Baral R, Patnaik S, Das BR. Co-expression of p53 and c-myc proteins linked with advanced stages of betel and tobacco-related oral squamous cell carcinoma from eastern India. Eur J Oral Sci 1998;106:907-13.
65. Levinson AD. Normal and activated ras oncogenes and their encoded products. Trends Genet 1986;2:81-5.
66. Kuo MY, Chang HH, Hahn LJ, Wang JT, Chiang CP. Elevated ras p21 expression in oral premalignant lesions and squamous cell carcinoma in Taiwan. J Oral Pathol Med 1995;24:255-60.
67. Chang SE, Bhatia P, Johnson NW, Morgan PR, McCormick F, Young B, et al. ras mutations in United Kingdom examples of oral malignancies are infrequent. Int J Cancer 1991;48:409-12.
68. Field JK, Yiagnisis M, Spandidos DA, Gosney JR, Papadimitriou K, Vaughan ED, et al. Low levels of ras p21 oncogene expression correlate with clinical outcome in head and neck squamous cell carcinoma. Eur J Surg Oncol 1992;18:168-76.
69. Warnakulasuriya KA, Chang SE, Johnson NW. Point mutations in the H-ras oncogene are detectable in formalin-fixed tissues of oral squamous cell carcinoma, but are infrequent in British cases. J Oral Pathol Med 1992;21:225-9.
70. McDonald JS, Jones H, Pavelic ZP, Pavelic LJ, Stambrook PJ, Gluckman JL. Immunohistochemical detection of the H-ras, K-ras and N-ras oncogenes in squamous cell carcinoma of the head and neck. J Oral Pathol Med 1994;23:342-6.
71. Kiaris H, Spandidos DA, Jones AS, Vaughan ED, Field JK. Mutations, expression and genomic instability of the H-ras proto oncogene in squamous cell carcinoma of the head and neck. Br J Cancer 1995;72:123-8.
72. Das N, Majumder J, DasGupta UB. Ras gene mutations in oral cancer in eastern India. Oral Oncol 2000;36:76-80.
73. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily, Sequence identity with the Fas antigen. J Biol Chem 1992;267(15):10 709-15.
74. Peli J, Schroter M, Rudaz C, Hahne M, Meyer C, Reichmann E, et al. Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. EMBO J 1999 Apr 1;18(7):1824-31.
75. Chen Q, Samaranayake LP, Zhen X, Luo G, Nie M, Li B. Up-regulation of Fas ligand and down-regulation of Fas expression in oral carcinogenesis. Oral Oncol 1999;35:548-53.
76. Loro LL, Vintermyr OK, Johannessen AC, Liavaag PG, Jonsson R. Suppression of Fas receptor and negative correlation of Fas ligand with differentiation and apoptosis in oral squamous cell carcinoma. J Oral Pathol Med 1999;28:82-7.
77. Muraki Y, Yoshioka C, Tateishi A, Fukuda J, Haneji T, Kobayashi N. Localization of Fas antigen in oral squamous cell carcinoma. Br J Oral Maxillofac Surg 1999;37:37-40.
78. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, et al. The RNA component of human telomerase. Science 1995;269:1236-41.
79. Curran AJ, St Denis K, Irish J, Gullane PJ, MacMillan C, KamelReid S. Telomerase activity in oral squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1998;124:784-8.
80. Miyoshi Y, Tsukinoki K, Imaizumi T, Yamada Y, Ishizaki T, Watanabe Y, et al. Telomerase activity in oral cancer. Oral Oncology 1999;35:283-9.
81. Patel MM, Patel DD, Parekh LJ, Raval GN, Rawal RM, Bhatavdekar JM, et al. Evaluation of telomerase activation in head and neck cancer. Oral Oncology 1999;35:510-5.